51
|
Hara H, Daiko H, Kato K, Igaki H, Kadowaki S, Tanaka Y, Hamamoto Y, Matsushita H, Nagase M, Hosoya Y, Tahara M. Final results of feasibility study of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) for clinical stage II/III esophageal squamous cell carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4060] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
52
|
Sawaki A, Ohashi Y, Omuro Y, Satoh T, Hamamoto Y, Boku N, Miyata Y, Takiuchi H, Ohtsu A. The use of trastuzumab in Japanese patients with HER2-positive advanced or metastatic gastric cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
102 Background: The Trastuzumab for Gastric Cancer (ToGA) study showed the efficacy of trastuzumab for HER2-positive gastric cancer (HGA). The aim of this study is to evaluate the benefit of trastuzumab for Japanese HGA patients. Methods: ToGA was an open-label, international, phase III, randomized controlled trial undertaken in 122 centers in 24 countries. Median overall survival (OS) was 13.8 months in those assigned to trastuzumab plus chemotherapy (C+T) compared with 11.1 months in those assigned to chemotherapy alone (C) with hazard (HR) ratio of 0.74. Subgroup analyses of patients enrolled from Japan were undertaken to estimate the hazard ratio (HR) for OS in the Japanese population. Based upon the prescribed protocol for Japan, we calculated HR using multiple Cox regression model with prespecified covariates in the ToGA study in order to make up for the small number of Japanese patients and reduce the bias in the baseline characteristics between two groups. Results: Sixteen institutes participated and 102 patients were enrolled, of which 101 patients were evaluable for this research. The median OS was 15.9 months in C+T arm versus 17.7 months in C arm. The HR for OS was 1.00 [95% CI: 0.59-1.69]. However, the HR for OS adjusted for the above covariates was estimated to be 0.68 [95% CI: 0.36-1.27]. There were differences between C+T arm and C arm in some baseline characteristics. Higher frequencies were seen in C arm as follow: intestinal type, prior gastrectomy, and smaller number of metastatic sites. For HER2 status, the percentage of patients with IHC0/FISH+ was lower in C+T arm (5.9%) than in C arm (18.0%), while that of patients with HER2 status IHC2+/FISH+ was higher in C+T arm (35.3%) than in C arm (26.0%). Conclusions: Although ToGA's overall OS HR = 0.74 (p = 0.0046), in the Japan patient subgroup, the unadjusted hazard ratio was 1.00. However, there was an imbalance of the baseline characteristics between the treatment arms in Japanese population. When adjusted for these characteristics, the HR was 0.68 which is similar to those in the ToGA study. Adding trastuzumab to chemotherapy in Japanese population appears to confer a similar magnitude of benefit compared to the whole population enrolled in the ToGA study. [Table: see text]
Collapse
Affiliation(s)
- A. Sawaki
- Aichi Cancer Center Hospital, Nagoya, Japan; Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan; Tokyo Metropolitan Komagome Hospital, Tokyo, Japan; Kinki University School of Medicine, Osaka, Japan; Tochigi Cancer Center, Tochigi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Department of Gastroenterology, Saku Central Hospital, Nagano, Japan; Osaka Medical College, Takatsuki, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - Y. Ohashi
- Aichi Cancer Center Hospital, Nagoya, Japan; Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan; Tokyo Metropolitan Komagome Hospital, Tokyo, Japan; Kinki University School of Medicine, Osaka, Japan; Tochigi Cancer Center, Tochigi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Department of Gastroenterology, Saku Central Hospital, Nagano, Japan; Osaka Medical College, Takatsuki, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - Y. Omuro
- Aichi Cancer Center Hospital, Nagoya, Japan; Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan; Tokyo Metropolitan Komagome Hospital, Tokyo, Japan; Kinki University School of Medicine, Osaka, Japan; Tochigi Cancer Center, Tochigi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Department of Gastroenterology, Saku Central Hospital, Nagano, Japan; Osaka Medical College, Takatsuki, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - T. Satoh
- Aichi Cancer Center Hospital, Nagoya, Japan; Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan; Tokyo Metropolitan Komagome Hospital, Tokyo, Japan; Kinki University School of Medicine, Osaka, Japan; Tochigi Cancer Center, Tochigi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Department of Gastroenterology, Saku Central Hospital, Nagano, Japan; Osaka Medical College, Takatsuki, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - Y. Hamamoto
- Aichi Cancer Center Hospital, Nagoya, Japan; Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan; Tokyo Metropolitan Komagome Hospital, Tokyo, Japan; Kinki University School of Medicine, Osaka, Japan; Tochigi Cancer Center, Tochigi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Department of Gastroenterology, Saku Central Hospital, Nagano, Japan; Osaka Medical College, Takatsuki, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - N. Boku
- Aichi Cancer Center Hospital, Nagoya, Japan; Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan; Tokyo Metropolitan Komagome Hospital, Tokyo, Japan; Kinki University School of Medicine, Osaka, Japan; Tochigi Cancer Center, Tochigi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Department of Gastroenterology, Saku Central Hospital, Nagano, Japan; Osaka Medical College, Takatsuki, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - Y. Miyata
- Aichi Cancer Center Hospital, Nagoya, Japan; Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan; Tokyo Metropolitan Komagome Hospital, Tokyo, Japan; Kinki University School of Medicine, Osaka, Japan; Tochigi Cancer Center, Tochigi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Department of Gastroenterology, Saku Central Hospital, Nagano, Japan; Osaka Medical College, Takatsuki, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - H. Takiuchi
- Aichi Cancer Center Hospital, Nagoya, Japan; Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan; Tokyo Metropolitan Komagome Hospital, Tokyo, Japan; Kinki University School of Medicine, Osaka, Japan; Tochigi Cancer Center, Tochigi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Department of Gastroenterology, Saku Central Hospital, Nagano, Japan; Osaka Medical College, Takatsuki, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - A. Ohtsu
- Aichi Cancer Center Hospital, Nagoya, Japan; Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan; Tokyo Metropolitan Komagome Hospital, Tokyo, Japan; Kinki University School of Medicine, Osaka, Japan; Tochigi Cancer Center, Tochigi, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Department of Gastroenterology, Saku Central Hospital, Nagano, Japan; Osaka Medical College, Takatsuki, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | | |
Collapse
|
53
|
Kato K, Hara H, Daiko H, Igaki H, Hamamoto Y, Nagase M, Kadowaki S, Tahara M. Feasibility study of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) for clinical stage II/III esophageal squamous cell carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.95] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
95 Background: In JCOG 9907, neoadjuvant chemotherapy with cisplatin and 5-fluorouracil (CF) improved overall survival without additional serious adverse events in treating stage II/III esophageal squamous cell carcinoma (ESCC). However, ESCC patient survival remains unsatisfactory. We conducted a feasibility study of neoadjuvant chemotherapy with docetaxel plus CF (DCF) for clinical stage II/III ESCC. Methods: Eligibility criteria included clinical stage II/III (non-T4) ESCC, PS 0–1, and age 20–70 years. Chemotherapy consisted of a 1-h infusion of docetaxel at 70 mg/m2 and 2-h infusion of cisplatin at 70 mg/m2 (day 1), and continuous infusion of 5-FU 750 mg/m2 (days 1 to 5). Antibiotic prophylaxis on days 5 to 15 was mandatory. This regimen was repeated every 3 weeks (maximum 3 cycles) until unacceptable toxicity, patient refusal, or disease progression was observed. After chemotherapy completion, transthoracic esophagectomy with extended (> D2) lymphadenectomy was performed. The primary endpoint was the completion rate of protocol treatment. Results: From July 2009 to Feb 2010, 34 patients were enrolled, including 2 ineligibles. The 32 eligibles had a median age of 61 (range 36–70; male/female: 30/2), with PS0/1 of 20/12 and cStage IIA/IIB/III of 6/8/18. During chemotherapy, the most common grade-3 or -4 toxicities were neutropenia (88%), febrile neutropenia (3%), anorexia (9%), and stomatitis (6%). Thirty-one (97%) patients underwent surgery. The protocol completion rate was 87.5% (28/32). No treatment-related death was observed, and the operative morbidity incidence was comparable to those in previous studies. According to RECIST, the overall response rate was 61.5% after DCF completion. Primary-lesion pathological complete response was achieved in 26% of patients (8/31) who underwent esophagectomy. Conclusions: Neoadjuvant DCF was well tolerated. Although these data are preliminary, the protocol is highly promising and warrants further investigation. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. Kato
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Tochigi Cancer Center, Tochigi, Japan; Jichi Medical University Hospital, Tochigi, Japan; Saitama Cancer Center, Saitama, Japan
| | - H. Hara
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Tochigi Cancer Center, Tochigi, Japan; Jichi Medical University Hospital, Tochigi, Japan; Saitama Cancer Center, Saitama, Japan
| | - H. Daiko
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Tochigi Cancer Center, Tochigi, Japan; Jichi Medical University Hospital, Tochigi, Japan; Saitama Cancer Center, Saitama, Japan
| | - H. Igaki
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Tochigi Cancer Center, Tochigi, Japan; Jichi Medical University Hospital, Tochigi, Japan; Saitama Cancer Center, Saitama, Japan
| | - Y. Hamamoto
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Tochigi Cancer Center, Tochigi, Japan; Jichi Medical University Hospital, Tochigi, Japan; Saitama Cancer Center, Saitama, Japan
| | - M. Nagase
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Tochigi Cancer Center, Tochigi, Japan; Jichi Medical University Hospital, Tochigi, Japan; Saitama Cancer Center, Saitama, Japan
| | - S. Kadowaki
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Tochigi Cancer Center, Tochigi, Japan; Jichi Medical University Hospital, Tochigi, Japan; Saitama Cancer Center, Saitama, Japan
| | - M. Tahara
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Tochigi Cancer Center, Tochigi, Japan; Jichi Medical University Hospital, Tochigi, Japan; Saitama Cancer Center, Saitama, Japan
| |
Collapse
|
54
|
Hamamoto Y, Sugawara Y, Inoue T, Kataoka M, Ochi T, Takahashi T, Sakai S. Relationship between Pretreatment FDG Uptake and Local Control after Stereotactic Body Radiotherapy in Stage I Non-small-cell Lung Cancer: The Preliminary Results. Jpn J Clin Oncol 2011; 41:543-7. [DOI: 10.1093/jjco/hyq249] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
|
55
|
Kume N, Fujioka Y, Taniguchi A, Tanaka K, Kagimoto S, Hirata K, Nakamura Y, Yamamoto T, Fujimoto S, Hamamoto Y, Tsuda K, Inagaki N, Seino Y, Koshiyama H. MS41 PITAVASTATIN REDUCES HIGH-SENSITIVITY C-REACTIVE PROTEIN AND IMPROVES LIPID PROFILES IRRESPECTIVELY OF BODY MASS INDICES – SUBANALYSIS OF KISHIMEN MULTI-CENTER PROSPECTIVE STUDY. ATHEROSCLEROSIS SUPP 2010. [DOI: 10.1016/s1567-5688(10)70542-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
56
|
Takiuchi H, Fukuda H, Boku N, Shimada Y, Nasu J, Hamamoto Y, Hironaka S, Yamaguchi K, Takashima A, Ohtsu A. Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4052] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
57
|
Chung HC, Bang Y, Van Cutsem E, Kang Y, Hamamoto Y, Moiseyenko V, Gotovkin E, Urspruch A, Ducournau P. (Q)-TWiST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4048] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
58
|
Hamamoto Y, Kataoka M, Semba T, Uwatsu K, Sugawara Y, Inoue T, Sakai S, Takahashi T, Aono S. Factors Affect the Survival Time after Recurrence in Stage III Non–small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.1073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
59
|
Hamamoto Y, Ogata T, Morino T, Hino M, Yamamoto H. Prostaglandin E1 analog increases spinal cord blood flow at the point of compression during and after experimental spinal cord injury. Spinal Cord 2009; 48:149-53. [PMID: 19687798 DOI: 10.1038/sc.2009.99] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
STUDY DESIGN An in vivo study using a spinal cord compression model in rats. OBJECTIVES To evaluate the effect of prostaglandin E1 (PGE1) on the change in thoracic spinal cord blood flow and on hind-limb motor function. BACKGROUND Until now, effect of PGE1 on spinal cord blood flow at the point of compression has not been tested. METHODS Our newly developed blood flow measurement system was a combination of a noncontact-type Laser Doppler system and a spinal cord compression device. The rat thoracic spinal cord was exposed and spinal cord blood flow at the point of compression was measured before, during and after compression. The functioning of the animals' hind-limbs was evaluated by the BBB Scale and by measuring the frequency of voluntary standing. RESULTS During the compression period, spinal cord blood flow was significantly higher in the PGE1-treated rats than in the control rats, which did not receive PGE1. After decompression, the spinal cord blood flow rapidly recovered to about 60% of the precompression level in the control rats. When the animals were treated with PGE1, blood flow after decompression reached about 90% of the precompression level.Twenty-gram compression for 40 mins induced motor deficiencies in the rat hind-limbs. The application of PGE1 significantly improved motor function of the rat hind-limbs after spinal cord injury. CONCLUSIONS The application of PGE1 increased spinal cord blood flow during and after spinal cord compression, and improved motor function after the spinal cord injury.
Collapse
Affiliation(s)
- Y Hamamoto
- Department of Orthopaedic Surgery, Ehime University School of Medicine, Tohon City, Ehime, Japan
| | | | | | | | | |
Collapse
|
60
|
Hazama S, Okuyama Y, Kato T, Okayama N, Hinoda Y, Sakamoto J, Mishima H, Fujita Y, Hamamoto Y, Oka M. Use of genotype subset selections of multi-UGT1As polymorphisms to predict severe neutropenia and tumor responses of metastatic CRC patients received FOLFIRI regimen. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15038] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15038 Introduction: The pharmacogenetics of irinotecan indicate that a common polymorphism in the uridine diphosphate glucuronosyltransferase 1As (UGT1As) gene predict severe toxicity. However the tumor response to irinotecan is variable and unpredictable. Methods: Two multi-center phase II studies of FOLFIRI (FLIGHT-1 and FLIGHT-2 study) were conducted for patients with metastatic colorectal cancer (CRC) in Japan. FLIGHT-1 study was first-line chemotherapy, and FLIGHT-2 study was FOLFOX-refractory second-line chemotherapy. 103 patients have been enrolled in these studies (53 patients in FLIGHT-1 and 50 patients in FLIGHT-2) from 20 institutions by April 2007 from November 2005. Seventy one patients were analyzed UGT1As polymorphisms, UGT1A1*28 (TA6>TA7), UGT1A1*6 (G>A), UGT1A1*60 (T>C), UGT1A7 (N129K; T>G), UGT1A7 (-57 T>G), UGT1A9*22 (T10>T9). Results: Out of 71 patients, 34 had G3/4 neutropenia or leukopenia, and 23 had tumor responses (CR +PR). G3/4 neutropenia was more frequent in patients with *6, N129K(G), -57(G), *22 allele than patients without these allele (p<0.05). Other polymorphism was not the predictive factor for toxicity and tumor response, independently. On the other hand, genotype subset selection of multi-UGT1As polymorphisms was useful to predict severe toxicities and tumor responses. Only 7 patients of 22 patients with TA6/TA6 and T10/T10, or TA6/TA7 and -57(T/T), or *6(G/G) and *60(T/T) had grade3/4 toxicity. Similarly, high risk group of toxicity or high and low tumor responses groups was also predicted by genotype subset selections. Conclusions: Genotype subset selections of multi-UGT1As polymorphisms were the excellent predictor for severe toxicities and tumor responses of metastatic CRC patients received FOLFIRI regimen. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Hazama
- Yamaguchi University Graduate School of Medicine, Ube Yamaguchi, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minoh City Hospital, Minoh, Japan; Yamaguchi University Hospital, Ube Yamaguchi, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; National Hospital Organization Osaka National Hosp, Osaka, Japan; Yamaguchi University. Graduate School of Medicine, Ube, Japan
| | - Y. Okuyama
- Yamaguchi University Graduate School of Medicine, Ube Yamaguchi, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minoh City Hospital, Minoh, Japan; Yamaguchi University Hospital, Ube Yamaguchi, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; National Hospital Organization Osaka National Hosp, Osaka, Japan; Yamaguchi University. Graduate School of Medicine, Ube, Japan
| | - T. Kato
- Yamaguchi University Graduate School of Medicine, Ube Yamaguchi, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minoh City Hospital, Minoh, Japan; Yamaguchi University Hospital, Ube Yamaguchi, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; National Hospital Organization Osaka National Hosp, Osaka, Japan; Yamaguchi University. Graduate School of Medicine, Ube, Japan
| | - N. Okayama
- Yamaguchi University Graduate School of Medicine, Ube Yamaguchi, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minoh City Hospital, Minoh, Japan; Yamaguchi University Hospital, Ube Yamaguchi, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; National Hospital Organization Osaka National Hosp, Osaka, Japan; Yamaguchi University. Graduate School of Medicine, Ube, Japan
| | - Y. Hinoda
- Yamaguchi University Graduate School of Medicine, Ube Yamaguchi, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minoh City Hospital, Minoh, Japan; Yamaguchi University Hospital, Ube Yamaguchi, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; National Hospital Organization Osaka National Hosp, Osaka, Japan; Yamaguchi University. Graduate School of Medicine, Ube, Japan
| | - J. Sakamoto
- Yamaguchi University Graduate School of Medicine, Ube Yamaguchi, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minoh City Hospital, Minoh, Japan; Yamaguchi University Hospital, Ube Yamaguchi, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; National Hospital Organization Osaka National Hosp, Osaka, Japan; Yamaguchi University. Graduate School of Medicine, Ube, Japan
| | - H. Mishima
- Yamaguchi University Graduate School of Medicine, Ube Yamaguchi, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minoh City Hospital, Minoh, Japan; Yamaguchi University Hospital, Ube Yamaguchi, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; National Hospital Organization Osaka National Hosp, Osaka, Japan; Yamaguchi University. Graduate School of Medicine, Ube, Japan
| | - Y. Fujita
- Yamaguchi University Graduate School of Medicine, Ube Yamaguchi, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minoh City Hospital, Minoh, Japan; Yamaguchi University Hospital, Ube Yamaguchi, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; National Hospital Organization Osaka National Hosp, Osaka, Japan; Yamaguchi University. Graduate School of Medicine, Ube, Japan
| | - Y. Hamamoto
- Yamaguchi University Graduate School of Medicine, Ube Yamaguchi, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minoh City Hospital, Minoh, Japan; Yamaguchi University Hospital, Ube Yamaguchi, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; National Hospital Organization Osaka National Hosp, Osaka, Japan; Yamaguchi University. Graduate School of Medicine, Ube, Japan
| | - M. Oka
- Yamaguchi University Graduate School of Medicine, Ube Yamaguchi, Japan; Kyoto First Red Cross Hospital, Kyoto, Japan; Minoh City Hospital, Minoh, Japan; Yamaguchi University Hospital, Ube Yamaguchi, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; National Hospital Organization Osaka National Hosp, Osaka, Japan; Yamaguchi University. Graduate School of Medicine, Ube, Japan
| |
Collapse
|
61
|
Sumiyoshi Y, Hashine K, Niwakawa M, Yamaguchi R, Fujii H, Hamamoto Y, Fukino K. Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e16107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16107 Background: Sorafenib (SOR) is a multi-kinase inhibitor, targeting Raf kinase and the receptor tyrosine kinases VEGFR-2 and PDGFR-β. Interferon-α (IFN) is most commonly used for metastatic renal cell carcinoma (RCC) in Japan. In this phase I study, we investigated the safety profile, pharmacokinetics (PK), and tumor response of SOR/(recombinant)IFN combination in Japanese patients (pts) with RCC. Methods: After 2 weeks of IFN-alone treatment, a total of 18 pts (6 in each cohort) with unresectable/metastatic RCC received 28-day cycles of continuous SOR 200 (Cohort 1 [C1]) or (Cohorts 2 and 3 [C2 and C3]) 400 mg bid combined with intramuscular IFN 6 (C1 and C2) or 9 (C3) MIU three times a week (tiw). Objectives were safety/tolerability and recommended dose of SOR/IFN as primary, and tumor response and PK as secondary. Results: Pt characteristics were: median 64.5 y.o.; ECOG-PS 0:1, 14:4; prior anticancer therapy in 13 pts. All pts completed Cycle 1 and entered Cycle 2 or later cycles. At data cut-off (September 30, 2008), dose-limiting toxicities were reported in all cohorts, including G3 fatigue, G3 anorexia, and G3 skin disorders. Common drug-related grade 3/4 adverse events (AEs) included fatigue (50%), lipase increased (44%) and neutropenia (39%), all of which were reversible and manageable. AEs resulting in treatment discontinuation in Cycle 2 or later cycles were seen in 5 pts in Cohort 3. One death was reported in C1 at Cycle 18 due to gastrointestinal and intraabdominal hemorrhage. It seemed attributable to DIC accompanied by RCC. Five PR (1 in C1 and 4 in C3) and 11 SD (4 in C1, 5 in C2, and 2 in C3) were achieved as the best response. IFN had no relevant impact on PK of SOR. Conclusions: SOR/IFN combination has promise for clinical benefit in RCC, and its recommended dose was continuous SOR 400 mg bid and IFN 6 MIU tiw. [Table: see text]
Collapse
Affiliation(s)
- Y. Sumiyoshi
- Shikoku Cancer Center, Matsuyama, Ehime, Japan; Shizuoka Cancer Center Hospital, Shizuoka, Japan; Jichi Medical University, Tochigi, Japan; Tochigi Cancer Center Hospital, Tochigi, Japan; Bayer Yakuhin, Osaka, Japan
| | - K. Hashine
- Shikoku Cancer Center, Matsuyama, Ehime, Japan; Shizuoka Cancer Center Hospital, Shizuoka, Japan; Jichi Medical University, Tochigi, Japan; Tochigi Cancer Center Hospital, Tochigi, Japan; Bayer Yakuhin, Osaka, Japan
| | - M. Niwakawa
- Shikoku Cancer Center, Matsuyama, Ehime, Japan; Shizuoka Cancer Center Hospital, Shizuoka, Japan; Jichi Medical University, Tochigi, Japan; Tochigi Cancer Center Hospital, Tochigi, Japan; Bayer Yakuhin, Osaka, Japan
| | - R. Yamaguchi
- Shikoku Cancer Center, Matsuyama, Ehime, Japan; Shizuoka Cancer Center Hospital, Shizuoka, Japan; Jichi Medical University, Tochigi, Japan; Tochigi Cancer Center Hospital, Tochigi, Japan; Bayer Yakuhin, Osaka, Japan
| | - H. Fujii
- Shikoku Cancer Center, Matsuyama, Ehime, Japan; Shizuoka Cancer Center Hospital, Shizuoka, Japan; Jichi Medical University, Tochigi, Japan; Tochigi Cancer Center Hospital, Tochigi, Japan; Bayer Yakuhin, Osaka, Japan
| | - Y. Hamamoto
- Shikoku Cancer Center, Matsuyama, Ehime, Japan; Shizuoka Cancer Center Hospital, Shizuoka, Japan; Jichi Medical University, Tochigi, Japan; Tochigi Cancer Center Hospital, Tochigi, Japan; Bayer Yakuhin, Osaka, Japan
| | - K. Fukino
- Shikoku Cancer Center, Matsuyama, Ehime, Japan; Shizuoka Cancer Center Hospital, Shizuoka, Japan; Jichi Medical University, Tochigi, Japan; Tochigi Cancer Center Hospital, Tochigi, Japan; Bayer Yakuhin, Osaka, Japan
| |
Collapse
|
62
|
Ishii H, Furuse J, Boku N, Okusaka T, Ikeda M, Ohkawa S, Fukutomi A, Hamamoto Y, Nakamura K, Fukuda H. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15578 Background: Fluorouracil (5-FU) chemoradiotherapy has been accepted as standard care for locally advanced pancreatic cancer (LAPC); however, it has not been shown to be superior to chemotherapy alone in gemcitabine (Gem) era. The present multicenter phase II study was conducted to evaluate the efficacy and the safety for the screening of Gem monotherapy against LAPC. Methods: Eligibility criteria included the following: patients (pts) with histologically or cytologically proven pancreatic adenocarcinoma or adenosquamous carcinoma, pts with UICC clinical stage III (T4N0–1 and M0), all lesions are assumed to be included in the radiation field of 15 cm square, age 20 or older, no prior treatment for LAPC, ECOG performance status of 0, 1 or 2, and adequate organ function. Gem was given intravenously at a dose of 1,000 mg/m2 over 30 minutes on days 1, 8 and 15, repeated every 4 weeks until disease progression. The primary endpoint was %1-year overall survival. A sample size of 50 was required with one-sided alpha of 0.20, beta of 0.10, expected %1-year survival of 40% and threshold %1-year survival of 25%. Results: Between Jan. 06 and Feb. 07, 50 pts from 14 institutions were registered. Patient characteristics were: median age; 67.5 (45–80), male/female; 35/15, PS 0/1/2; 30/20/0, pancreatic head/body-tail; 26/24. The major grade 3–4 adverse events were neutropenia (62%), leucopenia (32%), thrombocytopenia (18%), fatigue (12%), infection-biliary tree (10%), anorexia (8%), and nausea (6%). Hematological toxicity was mostly transient and there was no episode of infection with grade 3–4 neutropenia. There were no treatment-related deaths during the study. Serum CA 19–9 level was reduced by >50% in 37.5% of 40 pts with baseline CA19–9 >100U/ml. Up to the final follow-up in Apr. 08, the median overall survival was 1.25 years (95% CI, 1.06–1.71 years) with a %1-year survival of 64.8% (95% CI, 49.6–76.4%), and the null hypothesis (%1-y survival=25%) was rejected (p<0.0001). Conclusions: Gem monotherapy demonstrated far better survival than historical data of 5-FU chemoradiotherapy in LAPC pts with mild toxicities. In future randomized trial, we will select Gem chemotherapy as a referential arm to compare with the chemoradiotherapy regimen which is under phase II evaluation for LAPC. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- H. Ishii
- Cancer Institute Hospital, Tokyo, Japan; Kyorin University, Mitaka, Tokyo, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; National Cancer Center, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Kanagawa Cancer Center, Yokohama, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Tochigi Cancer Center, Utsunomiya, Japan
| | - J. Furuse
- Cancer Institute Hospital, Tokyo, Japan; Kyorin University, Mitaka, Tokyo, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; National Cancer Center, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Kanagawa Cancer Center, Yokohama, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Tochigi Cancer Center, Utsunomiya, Japan
| | - N. Boku
- Cancer Institute Hospital, Tokyo, Japan; Kyorin University, Mitaka, Tokyo, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; National Cancer Center, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Kanagawa Cancer Center, Yokohama, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Tochigi Cancer Center, Utsunomiya, Japan
| | - T. Okusaka
- Cancer Institute Hospital, Tokyo, Japan; Kyorin University, Mitaka, Tokyo, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; National Cancer Center, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Kanagawa Cancer Center, Yokohama, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Tochigi Cancer Center, Utsunomiya, Japan
| | - M. Ikeda
- Cancer Institute Hospital, Tokyo, Japan; Kyorin University, Mitaka, Tokyo, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; National Cancer Center, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Kanagawa Cancer Center, Yokohama, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Tochigi Cancer Center, Utsunomiya, Japan
| | - S. Ohkawa
- Cancer Institute Hospital, Tokyo, Japan; Kyorin University, Mitaka, Tokyo, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; National Cancer Center, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Kanagawa Cancer Center, Yokohama, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Tochigi Cancer Center, Utsunomiya, Japan
| | - A. Fukutomi
- Cancer Institute Hospital, Tokyo, Japan; Kyorin University, Mitaka, Tokyo, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; National Cancer Center, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Kanagawa Cancer Center, Yokohama, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Tochigi Cancer Center, Utsunomiya, Japan
| | - Y. Hamamoto
- Cancer Institute Hospital, Tokyo, Japan; Kyorin University, Mitaka, Tokyo, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; National Cancer Center, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Kanagawa Cancer Center, Yokohama, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Tochigi Cancer Center, Utsunomiya, Japan
| | - K. Nakamura
- Cancer Institute Hospital, Tokyo, Japan; Kyorin University, Mitaka, Tokyo, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; National Cancer Center, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Kanagawa Cancer Center, Yokohama, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Tochigi Cancer Center, Utsunomiya, Japan
| | - H. Fukuda
- Cancer Institute Hospital, Tokyo, Japan; Kyorin University, Mitaka, Tokyo, Japan; Shizuoka Cancer Center, Nagaizumi, Japan; National Cancer Center, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan; Kanagawa Cancer Center, Yokohama, Japan; Shizuoka Cancer Center, Shizuoka, Japan; Tochigi Cancer Center, Utsunomiya, Japan
| |
Collapse
|
63
|
Matsumoto K, Ando M, Yamauchi C, Egawa C, Hamamoto Y, Kataoka M, Shuto T, Karasawa K, Kurosumi M, Kan N, Mitsumori M. Questionnaire Survey of Treatment Choice for Breast Cancer Patients with Brain Metastasis in Japan: Results of a Nationwide Survey by the Task Force of the Japanese Breast Cancer Society. Jpn J Clin Oncol 2008; 39:22-6. [DOI: 10.1093/jjco/hyn124] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
64
|
Hamamoto Y, Kataoka M. Pitfalls of Definition of Internal Target Volume Using Long-Time Scan CT. Int J Radiat Oncol Biol Phys 2007. [DOI: 10.1016/j.ijrobp.2007.07.1766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
65
|
Izumi N, Yoshizawa M, Ono Y, Kobayashi T, Hamamoto Y, Saito C. Periodontal regeneration of transplanted rat teeth subcutaneously after cryopreservation. Int J Oral Maxillofac Surg 2007; 36:838-44. [PMID: 17804198 DOI: 10.1016/j.ijom.2007.06.003] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2006] [Accepted: 06/28/2007] [Indexed: 11/19/2022]
Abstract
The periodontal regeneration of transplanted teeth after cryopreservation in liquid nitrogen overnight was previously examined using an animal model. The results showed that overnight cryopreservation did not have any severe adverse effects on periodontal healing. For clinical application, it is necessary to make the period of storage longer than in the preliminary study. In this study, the regeneration of periodontal tissues after cryopreservation for 4 weeks was examined. The maxillary molars of 4-week-old Wistar rats were extracted and transplanted into the abdominal subcutaneous tissue either immediately or after cryopreservation in a deep freezer at -80 degrees C. The donor teeth were frozen in a rate-controlling freezer. At 1, 2 and 4 weeks after transplantation, they were excised and observed under light microscopy. The cryopreserved teeth had acellular cementum with a rough surface at 1 week. With an increase in cementoblasts and the appearance of periodontal ligament and alveolar bone, the surface had become smooth at 2 weeks. There was no progressive root resorption. Although the process took somewhat more time, the teeth cryopreserved for 4 weeks showed regeneration that was similar to that of the immediately transplanted teeth.
Collapse
Affiliation(s)
- N Izumi
- Division of Reconstructive Surgery for Oral and Maxillofacial Region, Department of Tissue Regeneration and Reconstruction, Niigata University Graduate School of Medical and Dental Sciences, Gakkoucho-Dori, Niigata, Japan.
| | | | | | | | | | | |
Collapse
|
66
|
Ikeda H, Nkamura Y, Minamikawa J, Honjo S, Hamamoto Y, Wada Y, Nabe K, Koshiyama H. PO22-718 COMPARISON OF EFFECTS OF AMLODIPINE AND ANGIOTENSIN RECEPTOR BLOCKERS ON THE INTIMA-MEDIA THICKNESS OF CAROITD ARTERIAL WALL (AAA STUDY: AMLODIPINE VS ARB IN ATHEROSCLEROSIS STUDY). ATHEROSCLEROSIS SUPP 2007. [DOI: 10.1016/s1567-5688(07)71728-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
67
|
Wada Y, Fukushima M, Honjo S, Ikeda H, Nabe K, Nomura K, Hamamoto Y, Koshiyama H. PO21-678 LIVER FUNCTION MAY BE ASSOCIATED WITH DEVELOPMENT OF HYPERTENSION AND DIABETES MELLITUS IN JAPANESE MEN. ATHEROSCLEROSIS SUPP 2007. [DOI: 10.1016/s1567-5688(07)71688-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
68
|
Nabe K, Honjo S, Ikeda H, Wada Y, Nomura K, Hamamoto Y, Koh T, Tatsuoka Y, Koshiyama H. Diabetes insipidus and cognitive function. Med Hypotheses 2007; 69:764-6. [PMID: 17467188 DOI: 10.1016/j.mehy.2007.01.081] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2007] [Accepted: 01/23/2007] [Indexed: 10/23/2022]
Abstract
It has been well known that several neuropeptides may affect human behavior, and that some endocrinopathies are associated with impaired higher function of the brain. There have been increasing evidences that vasopressin has both peripheral and central effects, the latter of which is involved in memory. In experimental animals, male mice with a null mutation in the V1a receptor (V1aR) exhibit a profound impairment in social recognition and changes in anxiety-like behavior. An AVP fragment analog has been reported to facilitate memory retention and recall in mice through protein kinase C-independent pathways. In human, a few recent reports have suggested that a familial central diabetes insipidus, caused by a heterozygous mutation in the gene for vasopressin prohormone, have minor disturbances in central nervous system. Taken together, it is hypothesized that the subject with central diabetes insipidus may frequently present with an impaired cognitive ability. It is justified to examine the cognitive function, when we make a diagnosis of central diabetes insipidus and to perform a clinical study to investigate whether central diabetes insipidus may be associated with impairment of higher brain functions.
Collapse
Affiliation(s)
- K Nabe
- Center for Diabetes and Endocrinology, The Tazuke Kofukai Foundation Medical Research Institute, Kitano Hospital, Osaka 530-8480, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
69
|
|
70
|
Fujii M, Segawa Y, Nogami N, Hamamoto Y, Kataoka M, Komori E, Sawada S, Yamashita M, Shinkai T, Takashima S. Factors affecting the risk of brain metastases after chemoradiotherapy for locally advanced non-small-cell lung cancer (LA-NSCLC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17019 Background: With an improvement in treatment outcome in patients with LA-NSCLC undergoing radical chemoradiotherapy, brain metastasis has become a greater problem. We assessed the cumulative incidence of brain metastases and its risk factors in such patients with LA-NSCLC. Methods: Between 1993 and 2003, 85 consecutive patients with stage IIIA or IIIB NSCLC underwent chemoradiotherapy in our institution. The characteristics of these patients were as follows: median age, 64 years (range, 39 to 74 years); stage IIIA/IIIB, 30/55 patients; squamous-cell/nonsquamous-cell histologies, 39/46 patients. Concurrent and sequential chemoradiotherapy were administered for 78 and 7 patients, respectively. Only two patients underwent surgical resection after chemoradiotherapy. Fifty-seven patients received conventional thoracic radiotherapy with a total dose of 59.5 ± 1.4 Gy (range, 40 to 70 Gy), and 28 received twice-daily radiotherapy with a total dose of 71.5 ± 6.5 Gy (range, 43 to 86 Gy). Thirty-eight patients received a combination chemotherapy consisting of cisplatin and docetaxel, and the remaining 47 received the other platinum-based regimens. Results: At a median follow-up time of 51 months (range, 9 to 131 months), median survival time was 25 months, with a 3-year survival rate of 36.9%. The median disease-free survival time was 13 months. During treatment and observation periods, 21 (24.7%) patients had developed brain metastases. Thirteen (15.3%) patients experienced brain metastases as the first site of relapse, and in nine (10.6%), brain was the sole site of relapse. The cumulative risk of brain metastases was 15.4% at 1-year, 21.1% at 2-year, and 25.7% at 3-year, respectively. In a multivariate analysis using Cox proportional hazard model, T-factor (T4 vs. T1–3) was the most predictive of brain failure (hazard ratio, 3.51; 95% confidence interval, 1.35 to 9.13; p = 0.01). Conclusions: In patients with LA-NSCLC undergoing chemoradiotherapy, brain was one of the most common sites of failure when locoregional control was achieved. Although efficacy of prophylactic cranial irradiation (PCI) on survival remains unclear for such patients with NSCLC, identification of patients more likely to have a benefit from PCI would be useful. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Fujii
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Y. Segawa
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - N. Nogami
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - Y. Hamamoto
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - M. Kataoka
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - E. Komori
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - S. Sawada
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - M. Yamashita
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - T. Shinkai
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| | - S. Takashima
- National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
| |
Collapse
|
71
|
Koshiyama H, Honjo S, Hamamoto Y, Ikeda H, Wada Y. Drugs share antidiabetic and antiatherosclerotic actions through “the common soil”. Med Hypotheses 2006; 66:473-5. [PMID: 16321474 DOI: 10.1016/j.mehy.2005.10.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2005] [Accepted: 10/13/2005] [Indexed: 11/24/2022]
Abstract
There have been increasing evidences that atherosclerosis is not the result of diabetes mellitus, but that both type 2 diabetes mellitus and atherosclerosis may share common pathogenesis, as Stern proposed as 'common soil' hypothesis in 1995. There are several candidates for 'common soil', such as insulin resistance, vascular inflammation and endothelial dysfunction. Recently many of clinical studies have indicated that some drugs can prevent or delay the development of cardiovascular diseases (CVD). Furthermore, many studies have suggested that some classes of drugs may prevent the development of type 2 diabetes. It is to be noted that most of the drugs may have both actions, i.e., to prevent development of new diabetes and to prevent CVD. Furthermore, they are reported to inhibit inflammation or endothelial dysfunction. Taken together, it is hypothesized that the drug which may have antiatherogenetic action may also have antidiabetic action, and vice versa. This hypothesis may provide the new insights into perspectives of drug development both to prevent type 2 diabetes and to prevent CVD.
Collapse
Affiliation(s)
- H Koshiyama
- Center for Diabetes and Endocrinology, The Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, 2-4-20 Ohgimachi, Kita-Ku, 530-8480 Osaka, Japan.
| | | | | | | | | |
Collapse
|
72
|
Annaka Y, Hamamoto Y, Akatsu M, Maruyama K, Oota S, Murakami T. Development of MBR with reduced operational and maintenance costs. Water Sci Technol 2006; 53:53-60. [PMID: 16605017 DOI: 10.2166/wst.2006.075] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
To reduce MBR O&M costs, a new MBR process that conducts efficient simultaneous biological nitrogen and phosphorus removal (BNR) was developed. In the development of this process, various approaches were taken, including reduction of power demand, chemical consumption and sludge disposal costs. To address power demand reductions, air supply requirements for membrane cleaning were reduced. The process adopted an improved membrane that requires less air for cleaning than conventional membranes. It also introduced cyclic aeration, which alternately supplies washing air to the two series of membrane units. Adoption of biological phosphorus removal eliminated chemical costs for phosphorus removal and contributed to the reduction of sludge disposal costs. By combining these technologies, compared to conventional MBR processes, an approximately 27% reduction in O&M costs was achieved.
Collapse
Affiliation(s)
- Y Annaka
- Nishihara Environment Technology Inc., Shibaura 3-6-18 Minato-ku, Tokyo, Japan
| | | | | | | | | | | |
Collapse
|
73
|
Muto M, Hattori S, Yano T, Minashi K, Hamamoto Y, Mera K, Doi T, Ohtsu A, Yoshida S. Endoscopic salvage treatment for local failure after definitive chemoradiotherapy (CRT) for esophageal cancer (EC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Muto
- National Cancer Ctr Hosp East, Kashiwa, Japan
| | - S. Hattori
- National Cancer Ctr Hosp East, Kashiwa, Japan
| | - T. Yano
- National Cancer Ctr Hosp East, Kashiwa, Japan
| | - K. Minashi
- National Cancer Ctr Hosp East, Kashiwa, Japan
| | - Y. Hamamoto
- National Cancer Ctr Hosp East, Kashiwa, Japan
| | - K. Mera
- National Cancer Ctr Hosp East, Kashiwa, Japan
| | - T. Doi
- National Cancer Ctr Hosp East, Kashiwa, Japan
| | - A. Ohtsu
- National Cancer Ctr Hosp East, Kashiwa, Japan
| | - S. Yoshida
- National Cancer Ctr Hosp East, Kashiwa, Japan
| |
Collapse
|
74
|
Suga M, Yamaguchi M, Ichimiya M, Yoshikawa Y, Hamamoto Y, Muto M. A rare case of the cutaneous form of adult T-cell leukaemia/lymphoma: assessment of remission by PCR for clonal T-cell receptor gamma gene rearrangements in an electron beam-irradiated cutaneous lesion. Clin Exp Dermatol 2005; 30:40-2. [PMID: 15663501 DOI: 10.1111/j.1365-2230.2004.01641.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Adult T-cell leukaemia/lymphoma is a lymphoproliferative disorder aetiologically associated with human T-cell lymphotropic virus type I infection. A cutaneous lesion often develops in the disease, and in rare cases, is even the only manifestation. Here we report a rare case of 'cutaneous' adult T-cell leukaemia/lymphoma with neither atypical cells in the peripheral blood nor lymph node involvement. All nodular lesions were completely eliminated after local electron beam irradiation (20 Gy/nodule in total). To evaluate whether or not there were residual lymphoma cells in the skin, we performed PCR to detect clonal T cell receptor gamma gene rearrangements. The sample from the nodule before irradiation showed evidence of a rearranged band, which was not detected at the same site after treatment nor in any peripheral blood. The findings suggest that this procedure is useful for the evaluation of therapeutic effects and the early detection of lymphoma recurrence.
Collapse
MESH Headings
- Female
- Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor
- Humans
- Leukemia-Lymphoma, Adult T-Cell/genetics
- Leukemia-Lymphoma, Adult T-Cell/pathology
- Leukemia-Lymphoma, Adult T-Cell/radiotherapy
- Lymphoma, T-Cell, Cutaneous/genetics
- Lymphoma, T-Cell, Cutaneous/pathology
- Lymphoma, T-Cell, Cutaneous/radiotherapy
- Middle Aged
- Polymerase Chain Reaction/methods
Collapse
Affiliation(s)
- M Suga
- Department of Dermatology and Biomolecular Recognition, Yamaguchi University School of Medicine, Minami-Kogushi, Ube, Yamaguchi, Japan
| | | | | | | | | | | |
Collapse
|
75
|
|
76
|
Abstract
BACKGROUND AND STUDY AIMS A newly developed narrow-band imaging (NBI) technique, in which modified optical filters were used in the light source of a video endoscope system, was applied during colonoscopy in a clinical setting. This pilot study evaluated the clinical feasibility of the NBI system for evaluating colorectal lesions. PATIENTS AND METHODS A total of 43 colorectal lesions in 34 patients were included in the study. The quality of visualization of colorectal lesions and the accuracy of differentiation between neoplastic and non-neoplastic lesions using the NBI system were evaluated in comparison with results from conventional colonoscopy and with chromoendoscopy. RESULTS For pit pattern delineation, NBI was superior to conventional endoscopy (P < 0.001), but inferior to chromoendoscopy (P < 0.05). NBI achieved better visualization of the mucosal vascular network and of the hue of lesions than conventional endoscopy (P < 0.05). However there was no significant difference between NBI and chromoendoscopy in differentiating neoplastic from non-neoplastic lesions (both techniques had a sensitivity of 100 % and a specificity 75 %). This was better than the results of conventional colonoscopy (sensitivity 83 %, specificity 44 %; P < 0.05 for specificity). CONCLUSIONS These results suggest that in the examination of colonic lesions the NBI system provides imaging features additional to those of both conventional endoscopy and chromoendoscopy. For distinguishing neoplasms from non-neoplastic lesions, NBI was equivalent to chromoendoscopy.
Collapse
Affiliation(s)
- H Machida
- Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan
| | | | | | | | | | | | | |
Collapse
|
77
|
Suga M, Okuda M, Ogasawara Y, Yokoyama E, Hamamoto Y, Muto M. The histopathology of envenomation by Japanese viper bite. Br J Dermatol 2004; 151:249-50. [PMID: 15270912 DOI: 10.1111/j.1365-2133.2004.06068.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
78
|
Hamamoto Y, Fujimoto S, Inada A, Takehiro M, Nabe K, Shimono D, Kajikawa M, Fujita J, Yamada Y, Seino Y. Beneficial effect of pretreatment of islets with fibronectin on glucose tolerance after islet transplantation. Horm Metab Res 2003; 35:460-5. [PMID: 12953162 DOI: 10.1055/s-2003-41802] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The scarcity of available islets is an obstacle for clinically successful islet transplantation. One solution might be to increase the efficacy of the limited islets. Isolated islets are exposed to a variety of cellular stressors, and disruption of the cell-matrix connections damages islets. We examined the effect of fibronectin, a major component of the extracellular matrix, on islet viability, mass and function, and also examined whether fibronectin-treated islets improved the results of islet transplantation. Islets cultured with fibronectin for 48 hours maintained higher cell viability (0.146 +/- 0.010 vs. 0.173 +/- 0.007 by MTT assay), and also had a greater insulin and DNA content (86.8 +/- 3.6 vs. 72.8 +/- 3.2 ng/islet and 35.2 +/- 1.4 vs. 30.0 +/- 1.5 ng/islet, respectively) than islets cultured without fibronectin (control). Absolute values of insulin secretion were higher in fibronectin-treated islets than in controls; however, the ratio of stimulated insulin secretion to basal secretion was not significantly different (206.9 +/- 23.3 vs. 191.7 +/- 20.2% when the insulin response to 16.7 mmol/l glucose was compared to that of 3.3 mmol/l glucose); the higher insulin secretion was thus mainly due to larger islet cell mass. The rats transplanted with fibronectin-treated islets had lower plasma glucose and higher plasma insulin levels within 2 weeks after transplantation, and had more favorable glucose tolerance 9 weeks after transplantation. These results indicate that cultivation with fibronectin might preserve islet cell viability, mass and insulin secretory function, which could improve glucose tolerance following islet transplantation.
Collapse
Affiliation(s)
- Y Hamamoto
- Department of Metabolism and Clinical Nutrition, Graduate School of Medicine, Kyoto University, Japan. yoshiyuki,
| | | | | | | | | | | | | | | | | | | |
Collapse
|
79
|
Abstract
Long-term changes in craniopharyngioma treated with radiation therapy (RT) were investigated by computed tomography (CT) and/ or magnetic resonance (MR) imaging. Eight patients with craniopharyngioma were treated with incomplete resection or conservative surgical intervention followed by postoperative RT. The periods of tumor shrinkage were often long and varied (range: 6-68 months, mean: 29.1 months). Temporary enlargement of the solid component of a tumor usually occurs during RT and does not represent tumor progression. Cystic enlargement also occurs sometimes comparatively early after RT, and enlarged cysts often shrink with no treatment or with conservative treatment. These changes should be differentiated from tumor recurrence, with careful follow-up. After shrinkage, small solid or cystic nodules enhanced with contrast medium often remain. Long-term follow-up is necessary to differentiate uncontrolled tumors from controlled tumors with imaging modalities.
Collapse
Affiliation(s)
- Y Hamamoto
- Department of Radiology, Yamagata University School of Medicine, Iidanishi, Japan.
| | | | | | | |
Collapse
|
80
|
Nagai K, Ichimiya M, Yokoyama K, Hamamoto Y, Muto M. Successful treatment of non-segmental vitiligo: systemic therapy with sex hormone-thyroid powder mixture. Horm Res 2002; 54:316-7. [PMID: 11595825 DOI: 10.1159/000053279] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
We previously reported a patient with generalized vitiligo improved by oral administration of the drug for menopausal syndrome (sex hormone-thyroid powder mixture). In this study, we reevaluated the efficiency of this drug for vitiligo, and examined its pharmacological action in melanogenesis.
Collapse
Affiliation(s)
- K Nagai
- Department of Dermatology and Biomolecular Recognition, Yamaguchi University School of Medicine, Ube, Japan
| | | | | | | | | |
Collapse
|
81
|
Hamamoto Y, Goto T, Kawamura T, Taniguchi M, Takeuchi T, Sakai S. [Hyperdense renal cyst associated with papillary adenoma: a case report]. Hinyokika Kiyo 2001; 47:865-8. [PMID: 11828775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
An abnormal shadow in the chest of a 57-year-old male was detected during a medical checkup and careful investigation revealed a left posterior mediastinal tumor (neurinoma) and a clearly demarcated homogenous mass with dimensions of 16 x 12 mm and computed tomographic (CT) value of 79 H.U. in the superior pole of the right kidney. The content solution was sticky and blackish-green. Neoplastic degenerations of 8 x 4 and 5 x 5 mm were seen in the cyst. Partial nephrectomy, which included the cystic section, was conducted and papillary adenoma was pathologically diagnosed. Nine years after the operation, the patient is alive and neither relapse nor other abnormalities were detected.
Collapse
Affiliation(s)
- Y Hamamoto
- Department of Urology, Gifu Prefectural Hospital
| | | | | | | | | | | |
Collapse
|
82
|
Hamamoto Y, Goto T, Kawamura T, Taniguchi M, Takeuchi T, Sakai S. [A case of ileal conduit stenosis 13 years after construction]. Hinyokika Kiyo 2001; 47:759-61. [PMID: 11758363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
A 63-year-old male was admitted to our hospital with the complaint of bilateral hydronephroses. Total cystectomy and ileal conduit construction were performed because of bladder tumor (TCC, G2, pT2N0M0) in 1985. The patient remained asymptomatic, but bilateral hydronephroses was observed by ultrasonography in 1997. DTPA renogram showed the delayed excretion. Conduitgraphy and antegrade pyelography revealed that the conduit was narrow like a pinhole at 2 cm distal region from the anastomotic site of the urinary duct. The stenotic region was inflated by a 24 Fr inflation-balloon-catheter. Chronic inflammation, which was thought to be caused by infection, was detected at the stenotic conduit by biopsy. Hydronephroses disappeared after the operation and the postoperative course was uneventful.
Collapse
Affiliation(s)
- Y Hamamoto
- Department of Urology, Gifu Prefectural Hospital
| | | | | | | | | | | |
Collapse
|
83
|
Yoshii T, Hamamoto Y, Muraoka S, Teranobu O, Kuwamura K, Komori T. Pseudoankylosis of the mandible as a result of methyl methacrylate-induced inflammatory cicatricial contracture of the temporal muscle after cranioplasty. Br J Oral Maxillofac Surg 2001; 39:374-5. [PMID: 11601819 DOI: 10.1054/bjom.2000.0563] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Pseudoankylosis of the mandible after intracranial surgical procedure has been widely reported, and is usually caused by fibrosis of the temporal muscle as a result of injury during the operation. We present an unusual case of mandibular pseudoankylosis as a result of methyl methacrylate-induced aseptic inflammatory cicatricial contracture of the temporal muscle after cranioplasty.
Collapse
Affiliation(s)
- T Yoshii
- Department of Oral and Maxillofacial Surgery, Hyogo Prefectural Awaji Hospital, Sumoto, Japan.
| | | | | | | | | | | |
Collapse
|
84
|
Hamamoto Y, Tsuura Y, Fujimoto S, Nagata M, Takeda T, Mukai E, Fujita J, Yamada Y, Seino Y. Recovery of function and mass of endogenous beta-cells in streptozotocin-induced diabetic rats treated with islet transplantation. Biochem Biophys Res Commun 2001; 287:104-9. [PMID: 11549260 DOI: 10.1006/bbrc.2001.5563] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Islet transplantation corrects chronic hyperglycemia by augmentation of insulin supply from the graft tissue, but the role of endogenous beta-cells after transplantation is not clear. In the present study, we examined endogenous beta-cell function after glucose homeostasis had been reestablished by islet graft in streptozotocin (STZ)-induced diabetic rats. Fed plasma glucose levels in diabetic rats transplanted with a large number of islets (2500 islets) into the left kidney capsule soon became lower (139.8 +/- 8.2 mg/dl) and close to the level in controls (129.7 +/- 11.3 mg/dl), and IPGTT exhibited a pattern of plasma glucose response almost identical to control. The insulin and DNA contents, islet area, and the distribution of beta-cells that were markedly deteriorated in islets of STZ rats were significantly restored in transplanted rats. The insulin release in response to glucose or alpha-ketoisocaproate was less in STZ rats, while in islets of transplanted rats the secretion recovered to levels similar to controls. On the other hand, arginine-induced insulin release was conversely hyperresponsive in STZ rats, but in transplanted rats, the response was decreased similar to controls. Thus, as the plasma glucose level normalizes, residual beta-cells show a recovery of function that cannot be accounted for by the increase in mass alone.
Collapse
Affiliation(s)
- Y Hamamoto
- Department of Metabolism and Clinical Nutrition, Graduate School of Medicine, Kyoto University, 54 Syogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
85
|
Takeda T, Tsuura Y, Fujita J, Fujimoto S, Mukai E, Kajikawa M, Hamamoto Y, Kume M, Yamamoto Y, Yamaoka Y, Yamada Y, Seino Y. Heat shock restores insulin secretion after injury by nitric oxide by maintaining glucokinase activity in rat islets. Biochem Biophys Res Commun 2001; 284:20-5. [PMID: 11374865 DOI: 10.1006/bbrc.2001.4933] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Heat shock protein (hsp), including hsp70, has been reported to restore the glucose-induced insulin release suppressed by nitric oxide (NO). However, the mechanism underlying this recovery remains unclear. In the present study, we examine the effects, in rat islets, of heat shock on insulin secretion inhibited by a small amount of NO and also on glucose metabolism, the crucial factor in insulin release. Exposure to a higher dose (15 U/ml) of interleukin-1beta (IL-1beta) abolished the insulin release by stimulation of glucose or KCl in both control and heat shocked islets. In rat islets exposed to a lower dose (1.5 U/ml) of IL-1beta, insulin secretion in response to glucose, but not to glyceraldehydes (GA), ketoisocaproate (KIC), or KCl, was selectively impaired, concomitantly with lower ATP concentrations in the presence of 16.7 mM glucose, while such suppression of insulin secretion and ATP content was not observed in heat shock-treated islets. NO production in islets exposed to 1.5 U/ml IL-1beta was significantly, but only partly, decreased by heat shock treatment. The glucose utilization rate measurement using [5-3H]-glucose and [2-3H]-glucose and the glucokinase activity in vitro were reduced in islets treated with 1.5 U/ml IL-1beta. In heat shock-treated islets, glucose utilization and glucokinase activity were not affected by 1.5 U/ml IL-1beta. These data suggest that heat shock restores glucose-induced insulin release inhibited by NO by maintaining glucokinase activity and the glucose utilization rate in islets in addition to reducing endogenous NO production.
Collapse
Affiliation(s)
- T Takeda
- Department of Metabolism and Clinical Nutrition, Kyoto University, Kyoto, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
86
|
Goto T, Noguchi A, Hamamoto Y, Minoshima K, Taniguchi M, Takeuchi T, Sakai S, Iwata H, Sasaoka I. [Primary squamous cell carcinoma of the prostate forming a rectourethral fistula: a case report]. Hinyokika Kiyo 2001; 47:433-6. [PMID: 11496402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
Eleven cases of squamous cell carcinoma of the prostate have been previously reported in the Japanese medical literature. Patients with this type of carcinoma have dismal prognoses. Herein, we report a case in a 61-year-old man who was admitted to our hospital and whose chief complaints were dysuria and high fever. Pyuria, bacteriuria, and the results of a digital rectal examination suggested acute prostatitis. Despite the administration of antibiotics, the dysuria did not improve. A transrectal needle biopsy was performed, and histology of the tissue showed squamous cell carcinoma. After chemotherapy using methotrexate, pirarubicin, and cisplatin, total pelvic excentration was performed. At 12 months after the operation, the patient is alive with no evidence of the disease.
Collapse
Affiliation(s)
- T Goto
- Department of Urology, Gifu Prefectural Hospital
| | | | | | | | | | | | | | | | | |
Collapse
|
87
|
Yoshii T, Hamamoto Y, Muraoka S, Kohjitani A, Teranobu O, Furudoi S, Komori T. Incidence of deep fascial space infection after surgical removal of the mandibular third molars. J Infect Chemother 2001; 7:55-7. [PMID: 11406759 DOI: 10.1007/s101560170036] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2000] [Accepted: 12/04/2000] [Indexed: 10/27/2022]
Abstract
Nine hundred and ninety-three patients who underwent surgical removal of the mandibular third molars with oral antibiotic prophylaxis were examined to determine the incidence of postoperative deep fascial space infection and its background factors. Postoperative deep fascial space infection was observed in 8 of the patients (0.8%; 4 males and 4 females), and submandibular spaces were involved in all infected patients. Only 1 of these 8 patients was an immune compromised host. Patients aged 30 years or more had a significantly higher incidence of deep fascial space infection than those aged under 30. Five patients had partial bony impactions and 3 had complete bony impactions. However, the incidence of infection according to the molar positions was not significantly different between partial bony impaction and complete bony impaction. The 8 patients had not had pericoronitis preoperatively. The clinical courses of all were favorable after antibiotics were administered intravenously. In conclusion, the incidence of deep fascial space infection after removal of the mandibular third molars was low, at 0.8%. However, it may be desirable to remove the molars, if applicable, at a younger age because of the higher incidence of infection in patients aged over 30. The results of this study also offer information that will be useful as a basis for obtaining informed consent from patients whose mandibular third molars are to be removed.
Collapse
Affiliation(s)
- T Yoshii
- Department of Dentistry, Hyogo Prefectural Staff Health Center, 5-10-1 Shimoyamate-dori, Chuo-ku, Kobe 650-8567, Japan.
| | | | | | | | | | | | | |
Collapse
|
88
|
Abstract
Clarithromycin is one of the macrolide antibiotics used for cutaneous and respiratory system infections. Only a few cases of adverse cutaneous reactions to this drug have been reported. Here we report a rare case of clarithromycin-induced fixed drug eruption which could be reproduced by a peroral provocation test, whereas patch tests on both unaffected and residual pigmented skin yielded negative results. All cutaneous lesions that recurred due to the challenge test developed the same pigmentation after a short course of intravenous corticosteroid.
Collapse
Affiliation(s)
- Y Hamamoto
- Department of Dermatology, Yamaguchi University School of Medicine, Ube Yamaguchi, Japan
| | | | | | | |
Collapse
|
89
|
Hamamoto Y, Nagai K, Ichimiya M, Yamamoto K, Kinoshita E, Muto M. Regressive effect of intralesional injection of a moderate dose of recombinant interleukin-2 on carcinoma erysipeloides from gastric carcinoma. Clin Exp Dermatol 2001; 26:42-4. [PMID: 11260177 DOI: 10.1046/j.1365-2230.2001.00758.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Cutaneous metastatic diseases remain nearly incurable and a major medical challenge. It has been shown that interleukin-2 (IL-2) has potential as a therapeutic agent for various neoplastic diseases such as melanoma, renal cell carcinoma and myeloid leukaemia. However, IL-2 therapy for metastatic skin lesions has not been established yet. In the present study, we investigated the effect of recombinant IL-2 in a 79-year-old Japanese man with carcinoma erysipeloides, a rare type of cutaneous metastasis from gastric cancer. He was treated with an intralesional injection of rIL-2 (200 000 JRU) daily. Ten days after treatment, an erythematous plaque was eliminated almost completely leaving light brown pigmentation. A skin biopsy from the pigmented area revealed the absence of obvious tumour cells. These findings suggest that this cytokine should be considered for the clinical treatment of several inoperative metastatic cutaneous diseases, including gastric cancer.
Collapse
Affiliation(s)
- Y Hamamoto
- Department of Dermatology, Yamaguchi University School of Medicine, Japan
| | | | | | | | | | | |
Collapse
|
90
|
Abstract
The frequency of amyloid deposits in cases of seborrheic keratosis was investigated In addition, the origin of amyloid protein(s) in lichen amyloidosis, macular amyloidosis and seborrheic keratosis was studied by immunohistochemical staining using a panel of anti-cytokeratin (CK) monoclonal antibodies. Amyloid deposits were found in 41 of 327 specimens (12.5%) from 301 cases of seborrheic keratosis. Amyloid deposits in seborrheic keratosis reacted with 6 of 12 CK antibodies and in lichen and macular amyloidosis (20 specimens) reacted with 5 of 12 CK antibodies. In seborrheic keratosis, antibody DE-K10 (labeling CK10) reacted with amyloid in 17 of 36 cases, antibody 34betaE12 (labeling CK1, 5, 10, 14) reacted in 33 of 39 cases, and antibody MNF116 (labeling CK5, 6, 8, 17) reacted in 32 of 35 cases. Among 20 specimens from lichen and macular amyloidosis, the three antibodies reacted with amyloid in the following rates: 1 with antibody DE-K10, all 20 with antibody 34betaE12, and 6 with antibody MNF116. These results suggest that amyloid deposits in seborrheic keratosis and lichen and macular amyloidosis may derive from epidermal cytokeratins.
Collapse
Affiliation(s)
- K Inoue
- Department of Dermatology, Yamaguchi University School of Medicine, Ube, Japan.
| | | | | | | | | |
Collapse
|
91
|
Goto T, Noguchi A, Hamamoto Y, Taniguchi M, Takeuchi T, Sakai S, Yamada T, Fujihiro S, Ishiyama S. [A case of traumatic priapism]. Hinyokika Kiyo 2000; 46:907-10. [PMID: 11211810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
We report a case of high flow priapism secondary to arteriovenous fistula produced by perineal trauma in a 43-year-old patient. Diagnosis was based on the result of gasometry in cavernous blood and color doppler sonography. Superselective embolization of the deep artery of the penis was performed with good results. After 6 months of treatment, erection and sexual function were normal. Our case demonstrates that this procedure is a safe and effective therapy for high flow priapism.
Collapse
Affiliation(s)
- T Goto
- Department of Urology, Gifu Prefectural Hospital
| | | | | | | | | | | | | | | | | |
Collapse
|
92
|
Hamamoto Y, Tateno H, Ishida T, Muto M. Lack of association between promoter polymorphism of the tumor necrosis factor-alpha gene and psoriatic arthritis in Japanese patients. J Invest Dermatol 2000; 115:1162-4. [PMID: 11121160 DOI: 10.1046/j.1523-1747.2000.0202a-5.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
93
|
Abstract
Benign symmetrical lipomatosis (BSL) is a disease characterized by massively symmetrical fat deposits predominantly in the neck and shoulder girdle area. The disease is frequently associated with alcoholism, hepatopathy, glucose intolerance, hyperuricemia, and malignant tumors. We describe a patient with BSL of the dorsal surfaces of both hands.
Collapse
Affiliation(s)
- K Yamamoto
- Department of Dermatology, Yamaguchi University School of Medicine, 1-1-1, Minami-Kogushi, Ube 755-8505, Japan
| | | | | | | |
Collapse
|
94
|
Fujimoto S, Tsuura Y, Ishida H, Tsuji K, Mukai E, Kajikawa M, Hamamoto Y, Takeda T, Yamada Y, Seino Y. Augmentation of basal insulin release from rat islets by preexposure to a high concentration of glucose. Am J Physiol Endocrinol Metab 2000; 279:E927-40. [PMID: 11001778 DOI: 10.1152/ajpendo.2000.279.4.e927] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We have found that preexposure to an elevated concentration of glucose reversibly induces an enhancement of basal insulin release from rat pancreatic islets dependent on glucose metabolism. This basal insulin release augmented by priming was not suppressed by reduction of the intracellular ATP or Ca(2+) concentration, because even in the absence of ATP at low Ca(2+), the augmentation was not abolished from primed electrically permeabilized islets. Moreover, it was not inhibited by an alpha-adrenergic antagonist, clonidine. A threshold level of GTP is required to induce these effects, because together with adenine, mycophenolic acid, a cytosolic GTP synthesis inhibitor, completely abolished the enhancement of basal insulin release due to the glucose-induced priming without affecting the glucose-induced increment in ATP content and ATP-to-ADP ratio. In addition, a GDP analog significantly suppressed the enhanced insulin release due to priming from permeabilized islets in the absence of ATP at low Ca(2+), suggesting that the GTP-sensitive site may play a role in the augmentation of basal insulin release due to the glucose-induced priming effect.
Collapse
Affiliation(s)
- S Fujimoto
- Department of Metabolism and Clinical Nutrition, Graduate School of Medicine, Kyoto University, Kyoto 606 - 8507, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
95
|
Yoshii T, Hamamoto Y, Muraoka S, Teranobu O, Shigeta Y, Komori T. Traumatic dislocation of the mandibular condyle into the temporal fossa in a child. J Trauma 2000; 49:764-6. [PMID: 11038100 DOI: 10.1097/00005373-200010000-00030] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- T Yoshii
- Department of Oral and Maxillofacial Surgery, Hyogo Prefectural Awaji Hospital, Shimogamo, Sumoto, Japan
| | | | | | | | | | | |
Collapse
|
96
|
Hoshina Y, Hamamoto Y, Suzuki I, Nakajima T, Ida-Yonemochi H, Saku T. Melanotic neuroectodermal tumor of infancy in the mandible: report of a case. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 89:594-9. [PMID: 10807717 DOI: 10.1067/moe.2000.105519] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A case of melanotic neuroectodermal tumor of infancy occurring in the mandible is described. The patient was a 1-month-old boy with a rapidly growing tumor of the mandible. Computed tomography showed 2 well-defined osteolytic lesions in the right mandible. Histopathologic diagnosis of a biopsy specimen was melanotic neuroectodermal tumor of infancy. The tumor was excised with removal of the surrounding bone, but 1(1/2) months later it recurred, and segmental mandibulectomy and reconstruction of the defect with a titanium miniplate was performed. Retrospectively, evidence of recurrence was noted on computed tomography taken on the tenth postoperative day. The recurrence was caused by incomplete removal of the tumor. Histopathologically, the tumor cells of the recurrent lesion were dispersed extensively in the bone marrow, and bone remodeling was active. The surgical procedure may have stimulated tumor cell proliferation and reactive bone formation. The patient was followed for 2 years with no evidence of recurrence or metastasis.
Collapse
Affiliation(s)
- Y Hoshina
- Niigata University, First Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Niigata University, Japan
| | | | | | | | | | | |
Collapse
|
97
|
Hamamoto Y, Nagai K, Yasui H, Muto M. Hyperreactivity of pseudoxanthoma elasticum-affected dermis to vitamin D3. J Am Acad Dermatol 2000; 42:685-7. [PMID: 10727321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
A 68-year-old woman with pseudoxanthoma elasticum (PXE) was treated with oral vitamin D(3). After 2 weeks, new papules developed on the pre-existing plaques. Biopsy specimens of a fresh papule showed more abundant calcium deposition than before therapy. Electron microscopy revealed electron-lucent areas, which suggested unusual mineralization. From these findings, we propose that in patients with PXE, certain cutaneous tissues are highly sensitive to vitamin D(3), resulting in microdeposition of calcium salts.
Collapse
Affiliation(s)
- Y Hamamoto
- Department of Dermatology, Yamaguchi University School of Medicine, Yamaguchi, Japan
| | | | | | | |
Collapse
|
98
|
Noguchi A, Hamamoto Y, Minoshima K, Taniguchi M, Takeuchi T, Sakai S, Deguchi T. [Pheochromocytoma of the urinary bladder: a case report]. Hinyokika Kiyo 1999; 45:721-3. [PMID: 10586368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
A 49-year-old man was hospitalized with the chief complaint of coagulation in urine. The patient was not hypertensive. Cystoscopic examination showed a submucosal tumor in the left lateral wall of the bladder. A transurethral sonogram revealed a low echoic nodule. Transurethral resection of the tumor in the urinary bladder was performed. The histopathological diagnosis indicated pheochromocytoma. Blood pressure was stable. After operation, the patient's course was uneventful, and there has been no recurrence for one year after surgery. This patient is the 52nd patient with pheochromocytoma of the urinary bladder reported in the Japanese literature.
Collapse
Affiliation(s)
- A Noguchi
- Department of Urology, Gifu Prefectural Gifu Hospital
| | | | | | | | | | | | | |
Collapse
|
99
|
Nishino Y, Yasuda M, Yokoi S, Ehara H, Yamamoto N, Takahashi Y, Ishihara S, Deguchi T, Kawada Y, Takeda A, Sakai S, Takeuchi T, Taniguchi M, Minoshima K, Hamamoto Y, Kanimoto Y, Nakano M, Fujihiro S, Nezasa S, Matsuda T, Nagatani Y, Maeda S, Tamaki M, Saito A, Komeda H. [Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group]. Gan To Kagaku Ryoho 1999; 26:1869-73. [PMID: 10560414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
We performed a retrospective long-term study to evaluate the efficacy of intravesical instillation of Tokyo 172 strain Bacillus Calmette-Guerin (BCG) on carcinoma in situ (CIS) of the bladder. Between 1989 and 1998, 42 patients with CIS of bladder underwent intravesical instillation of BCG. In the follow-up period from 6 to 116 months (mean: 37.3 months), the efficacy rate of intravesical BCG instillation for CIS of the bladder was 81.0%. Two patients died from the bladder cancer. The non-recurrence rate in patients with grade 2 carcinoma (19 cases) was not significantly different from that in those with grade 3 carcinoma (23 cases). However, the recurrence rate in patients with secondary CIS (15 cases) was significantly higher than in those with primary CIS (27 cases). The recurrence of CIS was observed in 7 of 42 cases. In 6 of 7 patients, CIS recurred within one year after treatment. Total cystectomy was performed in 10 of 42 patients, and pathological findings of muscle layer invasion were detected in 8 patients. Although side effects occurred in 33 patients (77.5%), no clinically significant side effects were observed. Our results suggest that intravesical BCG therapy may be useful for the treatment of CIS of the bladder.
Collapse
Affiliation(s)
- Y Nishino
- Dept. of Urology, Gifu University School of Medicine
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
100
|
Toku K, Tanaka J, Fujikata S, Hamamoto Y, Horikawa Y, Miyoshi K, Tateishi N, Suzuki Y, Maeda N. Distinctions between microglial cells and peripheral macrophages with regard to adhesive activities and morphology. J Neurosci Res 1999; 57:855-65. [PMID: 10467257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
Activated microglial cells and peripheral macrophages are hardly distinguishable from the viewpoints of morphology and function. There are various immunological markers common to both microglial cells and peripheral macrophages. In the present study, however, we found that microglial cells have distinct characters in terms of adhesion and morphology. By using a "rheoscope," that is an apparatus to rheologically measure the strength of cell adhesion to substrates, rat microglial cells were found to attach to polystyrene dishes much more weakly than alveolar and peritoneal macrophages. Interferon-gamma (IFNgamma) strengthened the adhesion of alveolar and peritoneal macrophages, whereas it weakened that of microglial cells. Morphological changes of microglial cells induced by IFNgamma were also different from those of peripheral macrophages. Furthermore, alveolar and peritoneal macrophages produced NO in response to IFNgamma, while microglial cells did not. When cultured on astrocyte-derived extracellular matrix (AsECM) in serum-free medium, only microglial cells extended multiple ramified processes. Conversely, alveolar and peritoneal macrophages on AsECM shrunk their ruffling membrane and rounded up. These distinctions between microglial cells and macrophages may reflect differences in cell lineages as well as environments in which individual cells reside.
Collapse
Affiliation(s)
- K Toku
- Department of Physiology, School of Medicine, Ehime University, Shigenobu, Ehime, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|